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Patient A received his transplant in July 2001. Cardiac 
biopsies showed no rejection on a stable immuno- 
suppressive regimen of mycophenolate, tacrolimus and 
prednisone. Renal status was stable with a creatinine 
of 1.4mg/dl and CMV prophylaxis with ganciclovir 
and valganciclovir was used. PCP prophylaxis with 
pentamidine was given. In mid October a BAL culture 
grew Aspergillus and Nocardia. Treatment was begun 
with tmp/smz, imipenem, and caspofungin plus lipid 
formulation amphotericin B. Ventilatory support and 
chest tube drainage were needed, and CT imaging showed 
cranial involvement. The patient died in December. 
Patient B received his heart transplant in 1997. 
Surveillance heart biopsies showed no evidence of 
rejection and renal function was stable with a creatinine 
around 2mg/dl. PCP prophylaxis with tmp/smz was given 
for two years until July 1999. The patient developed 
persistent pleural effusions that reoccurred in spite of 
repeated drainage. Specimens from surgical decortication 
and evacuation of the effusions grew Nocardia that was 
treated with IV tmp/smz for one month. An MRI did not 
show any intracranial lesions. Outpatient treatment with 
oral tmp/smz was continued. 
The third patient received his transplant in February 
2001. Myocardial biopsies confirmed grade I and grade 
III rejection 2 months and 7 months post transplantation 
respectively. In the second instance a short-term increase 
in immunosuppression was given. The patient also 
received lamivudine and ganciclovir because the donor 
was hepatitis B core antibody positive and had positive 
CMV serology. Prophylaxis with tmp/smz three times 
weekly was begun in March. Renal function was stable. 
Subsequent to respiratory complaints a CT of the chest 
was obtained in October and showed a significant pul- 
monary lesion. Bronchoscopy specimens grew Nocardia 
and Aspergillus. Imaging of the head did not reveal any 
cranial involvement. IV treatment with caspofungin, 
imipenem and cefotaxime continued through the middle 
of December with improvement of the pulmonary 
lesions on repeat CT. The patient was discharged on 
outpatient oral therapy with tmp/smz and itraconazole. 
This uncanny cluster of nocardia infections in heart 
transplant patients exhibits the importance of consider- 
ing Nocardia as opportunistic pathogens in transplant 
patients even if tmp/smz prophylaxis has been given. 
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Introduction: Cytomegalovirus reactivation is common 
and carries serious morbidity and high mortality in 
patients undergoing allogeneic marrow transplantation, 
especially in recipients of marrow grafts from CMV- 
seropositive donors. The impact of early viral reactivation 
on response to antiviral treatment is uncertain. 
Methods: Seven recipients of two and greater than two 
HLA-antigen mismatched, related marrow transplant- 
ation during 1999-2000 were evaluated prospectively for 
CMV viremia by real-time PCR technique (Speciality 
Laboratories, Santa Monica, CA) performed on post- 
transplantation day + 1, and than weekly. All values are 
given in median+standard deviation. 
Results: Five had refractory or recurrent acute myelo- 
genous leukemia (AML), and two with acute lympho- 
cytic leukemia (ALL). Four received 3 HLA-antigen 
mismatched marrow grafts from a related donor. Three 
had evidence of CMV in the peripheral blood on 12+5 
days (age 17+11 years), whereas four (age 26+24 years) 
had evidence of reactivation on 30-t 4 days following 
BMT. In the sub-group with early reactivation (day 
12+5), median CMV viral load was 258+91 copies/ml, 
and 1291+4220 copies/ml in the remaining four (P~0.5). 
Four patients had clinical and virological failure to initial 
therapy with ganciclovir (5 mg/kg every 12 hours). 
Among these, two (2/3; 66.7%) patients had evidence of 
early CMV reactivation and the other two (2/4; 50%) 
had evidence of reactivation around post transplant day 
+30 (P>O.5). 
Conclusions: Cytomegalovirus reactivation during the 
first two weeks of transplantation was associated with 
low-grade viremia. We did not observed a significant 
association with early CMV reactivation and failure to 
initial ganciclovir therapy in patients following high-risk 
allogeneic marrow transplantation. 
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Background and objective:. The present study was 
undertaken to evaluate the therapeutic effects of 
pancreatic beta-cells in diabetic animals immunized by 
Escherichi coli vaccine. 
Study design/ materials and methods: Ten days after 
streptozocin injection (60 mg/ kg), diabetic rats received 
intraperitoneal injection of pancreatic beta-cells 
(5.7~10~ cells/rat). Twelve days later both the diabetic 
and healthy animals were immunized by oral route with 
enteroinvasive E. coli (0136 serotype) acetone-killed 
vaccine. Twenty-one days after beta-cells transplantation 
lamina propria and Peyer’s patches lymphoid T cells 
were obtained from the intestine. 
